Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
24 hedge funds and large institutions have $8.07M invested in Titan Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$3.44M |
| 2 |
PA
Perceptive Advisors
New York
|
+$2.36M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$342K |
| 4 |
Millennium Management
New York
|
+$277K |
| 5 |
Renaissance Technologies
New York
|
+$277K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $4K | – | – | – |
|
|
HNB
27
Huntington National Bank
Columbus,
Ohio
| $2K | – | – | – |
|
28
Simplex Trading
Chicago,
Illinois
| $1K | – | – | – |
|
TTNP Hedge Fund Activity: Q4 2015 in Review
24 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2015, worth a combined $8.07M.
Buyers outnumbered sellers: 24 funds opened new TTNP positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $3.44M.
- 24 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $8.07M of Titan Pharmaceuticals stock for Q4 2015.
- 24 funds opened new Titan Pharmaceuticals positions in Q4 2015 and 0 closed out, a net change of +24 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2015 was Broadfin Capital, an estimated $3.44M added.
Based on aggregated 13F filings for Q4 2015.